Cellectar Biosciences, Inc. (CLRB) intrinsic value & 10-year financials
Cellectar Biosciences, Inc. (CLRB) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.14
- Market cap
- $3.0M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -24273.3%
- Free cash flow (FY2025)
- -$23.1M
CLRB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$21.8M | -$8.35 | -$23.1M | — | 337.0% |
| FY2024 | — | -$44.6M | -$1.40 | -$47.7M | — | 544.7% |
| FY2023 | — | -$38.0M | -$1.04 | -$33.2M | — | 546.6% |
| FY2022 | — | -$28.6M | -$1.35 | -$25.4M | — | 913.0% |
| FY2021 | — | -$24.1M | -$0.25 | -$22.7M | — | 1057.6% |
| FY2020 | — | -$15.1M | -$0.61 | -$14.0M | — | 942.6% |
| FY2019 | — | -$14.1M | — | -$11.7M | — | 2513.2% |
| FY2018 | — | -$13.2M | — | -$11.8M | — | -249406.2% |
| FY2017 | — | -$13.6M | — | -$11.4M | — | -112.0% |
| FY2016 | — | -$6.2M | — | -$8.4M | — | -69.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Cellectar Biosciences, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Cellectar Biosciences, Inc. has historically struggled to out-earn its cost of capital, averaging just -260.7% ROIC.
Cellectar Biosciences, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Cellectar Biosciences, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.